Physician profile
Trudi E Fahey
NPI 1295751857
$4,564.41
in general payments reported to CMS, 2019-2025
25 companies · $452 in 2025
The $452 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $426 · 2021: $623 · 2022: $642 · 2023: $731 · 2024: $569 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.51 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $766.43 | 2019-2024 | Slynd |
| Abbvie INC. | $689.71 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $686.15 | 2021-2025 | |
| Astellas Pharma US INC | $465.46 | 2022-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $242.49 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $215.44 | 2023-2025 | Cologuard Collection Kit |
| Millicent US INC | $190.32 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Evofem Biosciences, INC. | $171.68 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $171.62 | 2019-2023 | |
| Therapeuticsmd, INC. | $167.46 | 2019-2022 | |
| Avion Pharmaceuticals | $100.02 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $84.45 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $83.61 | 2021-2022 | |
| Allergan, INC. | $73.40 | 2019-2020 | |
| Shield Therapeutics INC | $66.07 | 2022-2024 | Accrufer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $62.85 | 2019 | |
| Coopersurgical, INC. | $54.67 | 2020-2024 | Paragard T 380a |
| Organon LLC | $54.59 | 2022-2024 | Nexplanon |
| Lupin INC. | $44.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.97 | 2019-2020 | |
| Agile Therapeutics, INC. | $33.06 | 2021 | |
| Mission Pharmacal Company | $31.05 | 2019-2020 | |
| Roche Diagnostics Corporation | $30.79 | 2020 | |
| Merck Sharp & Dohme LLC | $23.78 | 2019 | |
| Ascend Therapeutics US, LLC | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trudi Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.